PROVISIONAL APPLICATION COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION under 37 CFR 1.53(c).

	Docket Number	11913.6003-00000			Type a plus sign (+) in	side this box =	+	
INVENTOR(s)/APPLICANT(s)								
LAST NAME		FIRST NAME	MIDDLE INITIAL	RESIDENCE (CITY AND EITHER STATE OR FOREIGN COUNTRY)		OREIGN		
GOLDSTEIN		David	М.	Red	Redwood City, CA			
TITLE OF INVENTION (500 characters max)								
FORMULATIONS								
CORRESPONDENCE ADDRESS								
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P., Customer Number 22,852								
ENCLOSED APPLICATION PARTS (check all that apply)								
Specification: 44 Pages Drawing(s): [Number] Sheets/[Number] Figures								
Other: [Number] Pages; [Description]								
METHOD OF PAYMENT								
8	The filing fees	are submitted	PR	OVISIC	SIONAL FILING FEE \$250.00			
	herewith. The Commiss authorized to deficiency or o overpayment Account Num	tioner is hereby charge any credit any in fees to Deposit ber 06-0916.	Tot sec tha frac	tal Num quence in 100 p ction the	er of Pages of specification, drawings, computer listing, or other papers 45. If more ges, add \$310 for each additional 50 pages or eof.			
			it			\$0 (Size Fee)		
			Re	duction	by 1/2 For Small Entity	\$		
				TAL FI		\$250.00		
The invention was made by an agency of the United States Government or under a contract with an								

agency of the United States Government.

No.

Yes, the name of the U.S. Government agency and the Government contract number are:

Respectfully submitted on behalf of the patent practitioners associated with Customer Number 22,852,

RM

DOCKF

Date June 29, 2012

TYPED OR PRINTED NAME Wen Li, Ph.D. Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P. Telephone: 650.849.6649

REGISTRATION NO. 62,185

Additional inventors are being named on separately numbered sheets attached hereto.

PROVISIONAL APPLICATION FILING ONLY

Find authenticated court documents without watermarks at docketalarm.com.

5	
10	
15	
	FORMULATIONS
20	Inventor David Goldstein
25	
30	
35	
40	
45	

Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

FORMULATIONS

The present disclosure provides certain oral pharmaceutical formulations of ibrutinib, certain methods for their administration, certain processes of their production, and certain uses of these formulations for the treatment of diseases treatable by ibrutinib such as cancer and autoimmune diseases.

Bruton's tyrosine kinase (BTK) is a member of the Tec tyrosine kinase family. BTK is expressed in most hematopoietic cells such as B cells, mast cells, and macrophages but not

- 10 in T cells, natural killer cells, and plasma cells. Btk plays a role in the development and activation of B cells. Mutations in the human BTK gene cause the inherited disease X-linked agammaglobulinemia (XLA), with lack of peripheral B cells and low levels of serum Ig. In XLA, the primary immune deficit is B cell specific. The development of drugs which inhibit BTK can have therapeutic significance in the treatment of both B cell-related hematological
- 15 cancers (e.g. non-Hodgkin lymphoma (NHL) and B cell chronic lymphocytic leukemia (B-CLL), and autoimmune diseases (e.g. rheumatoid arthritis, Sjogrens syndrome, IBD, lupus, and asthma).

PCI-32765 (ibrutinib) is disclosed in U.S. Patent No. 7,514,444, issued on April 7, 2009, and has the following structure:



20

5

Ibrutinib is an orally available drug that targets Bruton's tyrosine kinase (BTK). Ibrutinib, is an irreversible small molecule BTK inhibitor that is in Ph Ib/II of clinical trials in a variety of B-cell malignancies including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), and diffuse large B-cell

25 lymphoma (DLBCL) and multiple myeloma (cancer of plasma cells, a type of white blood cell present in bone marrow). At present ibrutinib is administered orally in clinical trials, via the gastrointestinal tract, at high clinical doses (420 mg/day or 840 mg/day) to patients with CLL and SLL to obtain the desired thereapeutic effect. The need for such high doses of

ibrutinib may be due to low bioavailability (the oral bioavailability of ibrutinib is reported to be 22.8% in rats) and may be responsible for the adverse side effects associated with the use of ibrutinib such as nausea or emesis, dizziness and diarrhea. Moreover, low bioavailability results in more variable absorption and potential variability of the desired therapeutic response.

5

30

35

As stated above, at present ibrutinib is administered orally, via the gastrointestinal tract, at high clinical doses (420 mg/day or 840 mg/day) to patients to obtain the desired clinical benefit. It is presently disclosed that when ibrutinib is administered intraduodenally versus via the gastrointestinal tract in rats, the oral bioavailability of ibrutinib unexpectedly

- 10 increased from 21 % to 100% as determined by AUC. This unexpected increase in oral bioavailability of ibrutinib can translate into a number of desirable practical benefits. The increase in oral bioavailability should enable administration of ibrutinib at a significantly lower therapeutically effective dose than is currently being used. The lower variability associated with this greater bioavailability should lead to a more reliable therapeutic response
- 15 as well as more predictable drug absorption. And avoidance of exposure of Ibtrutinib to the stomach and/or use of lower therapeutically effective dose of ibrutinib can reduce or altogether eliminate potential adverse side effects of this drug such as diahrrea, nausea or emesis, and dizziness. U.S. Patent No. 7,514,444, mentioned above, discloses administration of 0.02-5000 mg/kg and1-1500 mg of ibrutinib/per day and in clinical trials 420 or 840
- 20 mg/day of ibrutinib is being administered to the patients with CLL and SLL. There is no reasonable expectation n the art that ibrutinib can be administered orally at lower efficacious doses to the patients with CLL and SLL, particularly as evidenced by the 420 or 840 mg/day of ibrutinib being administered in clinical trials to those patients. Moreover, other than for active agents that are unstable in the stomach or at acidic pH delivery of any active agent
- 25 with low bioavailability further along in the gastrointestinal tract reduces the path length for drug absorption and would be expected to reduce bioavailability. That is a reason why it was unexpected that delivery of ibruntinib directly to the small intestine results in greater bioavailability.

Accordingly, in one aspect, the present disclosure provides a solid oral dosage form comprising:

- (i) ibrutinib and/or a pharmaceutically acceptable salt thereof;
- (ii) means for release of ibrutinib in the intestine; and
- (iii) at least one pharmaceutically acceptable excipient.

. In one embodiment of above aspect, ibrutinib and/or a pharmaceutically acceptable salt thereof is released in the small intestine. In one embodiment, ibrutinib and/or a

Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

pharmaceutically acceptable salt thereof is released to a region of the intestine in which the pH is about 5, or 5, or greater than 5. In another embodiment, said ibrutinib and/or a pharmaceutically acceptable salt thereof is released to a region of the intestine in which the pH is about 5.5, or greater than about pH 5.5 or 5.5. For example, the release is in one or

- 5 more of the duodenum, jejunum, ileum, and colon. In one embodiment, the release is in one or more of the duodenum, jejunum, or ileum. In one embodiment, the release to the above regions of the intestine is achieved by coating ibrutinib and/or a pharmaceutically acceptable salt thereof or the dosage form containing ibrutinib and/or a pharmaceutically acceptable salt thereof with at least one coating chosen from enteric coatings and non-enteric time-delayed
- 10 release coatings. In one embodiment, the release to the above regions of the intestine is achieved by coating ibrutinib and/or a pharmaceutically acceptable salt thereof or the dosage form containing ibrutinib and/or a pharmaceutically acceptable salt thereof with at least one coating chosen from enteric coatings. In one embodiment, the release to the above regions of the intestine is achieved by coating ibrutinib and/or a pharmaceutically acceptable salt thereof
- 15 or the dosage form containing ibrutinib and/or a pharmaceutically acceptable salt thereof with at least one coating chosen from enteric coatings wherein the enteric coatings are choseb from polymeric coatings. When a non-enteric coating is employed, the time-delayed release dosage forms are administered in fasted state and the time-delayed release coating is designed to erode, burst, or become hightly permeable in about 0.3 to about 3 hours, and preferably in
- 20 about 0.5 to about 2 hours after administration to release ibrutinib and/or a pharmaceutically acceptable salt thereof.

In a second aspect, the present disclosure provides a solid oral dosage form comprising:

25

(i) ibrutinib and/or a pharmaceutically acceptable salt thereof;

(ii) means for increasing the oral bioavailability of ibrutinib, as measured by the area under the curve (AUC), as compared to when said ibrutinib and/or said pharmaceutically acceptable salt thereof are administered in an immediate release dosage form; and

(iii) at least one pharmaceutically acceptable excipient.

- In one embodiment of the second aspect, the increase in the oral bioavailability of ibrutinib and/or a pharmaceutically acceptable salt thereof is due to the release of the ibrutinib and/or a pharmaceutically acceptable salt thereof in the intestine. In another embodiment of the second aspect, the increase in the oral bioavailability of ibrutinib and/or a pharmaceutically acceptable salt thereof is due to the release of the ibrutinib and/or a pharmaceutically acceptable salt thereof is due to the release of the ibrutinib and/or a pharmaceutically acceptable salt thereof in the small intestine. In another embodiment of the
- 35 second aspect, ibrutinib and/or a pharmaceutically acceptable salt thereof is released in in

DOCKET



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

